Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alterity Therapeutics ( (AU:ATH) ) just unveiled an announcement.
Alterity Therapeutics reported a robust second quarter of FY26, highlighting strengthened Phase 2 data for its lead MSA candidate ATH434, further detailed through additional analyses and multiple international scientific presentations that reinforced a potential US$2.4 billion commercial opportunity. The company advanced regulatory preparations toward a pivotal Phase 3 program, including work toward an End-of-Phase-2 meeting with the U.S. FDA targeted for mid-2026, while refining trial design and operational readiness, exploring non-dilutive funding partnerships with pharmaceutical and corporate advisers, bolstering its board and executive leadership, and maintaining a solid cash balance of A$49.2 million to support its next stage of clinical and commercial development.
The most recent analyst rating on (AU:ATH) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.
More about Alterity Therapeutics
Alterity Therapeutics is a dual-listed biotechnology company (ASX: ATH, NASDAQ: ATHE) focused on developing disease-modifying treatments for neurodegenerative disorders, with a lead program targeting Multiple System Atrophy (MSA). The company’s primary asset, ATH434, is being advanced as a first-in-class therapy for MSA, supported by a global clinical and regulatory strategy and a strong cash position to fund late-stage development planning.
Average Trading Volume: 22,511,115
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$87M
For an in-depth examination of ATH stock, go to TipRanks’ Overview page.